STOCK TITAN
  1. Home
  2. News
  3. BDTX

Black Diamond Therapeutics Inc - BDTX STOCK NEWS

Welcome to our dedicated news page for Black Diamond Therapeutics (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Black Diamond Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Black Diamond Therapeutics's position in the market.

News
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
Black Diamond Therapeutics, a clinical-stage oncology company, will present data on BDTX-1535 for recurrent glioblastoma at the 2024 ASCO Annual Meeting. The presentations will cover Phase 1 dose escalation results and a Phase 0/1 trial conducted at the Ivy Brain Tumor Center. Dr. Patrick Wen and Yoshie Umemura will be presenting the data on June 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
News
Black Diamond Therapeutics Announces Changes to Board of Directors
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) appoints industry veterans Shannon Campbell and Prakash Raman to its Board of Directors, while Wendy Dixon and Alex Mayweg step down. The new members bring deep oncology expertise as the company advances BDTX-1535, a fourth-generation EGFR inhibitor, through Phase 2 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.85%
Tags
management
-
News
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Rhea-AI Summary
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGFR-mutant lung cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) will be presenting at various investor conferences to discuss their MasterKey therapies targeting oncogenic mutations in cancer patients. The presentations will be held in April 2024, featuring President and CEO, Mark Velleca, M.D., Ph.D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences
-
News
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Black Diamond Therapeutics, Inc. dosed the first patient in a Phase 2 trial of BDTX-1535 for NSCLC patients. The company reported robust financial results with $131.4 million in cash as of December 31, 2023. Key milestones include data releases for BDTX-1535 and BDTX-4933 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
earnings
-
News
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) to present at AACR Annual Meeting 2024 on evolving EGFR mutational landscape in NSCLC and BDTX-1535 profile targeting over 50 oncogenic EGFR mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
News
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) CEO, Dr. Mark A. Velleca, to participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference. The company is focused on developing MasterKey therapies for genetically defined cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
News
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) provided an update on their clinical programs, including BDTX-1535 for EGFR mutant NSCLC and GBM, and BDTX-4933 for KRAS mutant NSCLC. The FDA feedback allows the initiation of Phase 2 cohort for BDTX-1535 in first-line treatment of non-classical EGFR mutant NSCLC. Fast Track Designation was granted for BDTX-1535 as a second-line treatment for EGFR mutant/C797S NSCLC. Phase 2 results for 2L/3L patients with EGFR mutant NSCLC are expected in Q3 2024. Phase 1 clinical trial results and 'window of opportunity' data in patients with EGFR mutant GBM are anticipated to be presented in Q2 2024. Cash, cash equivalents, and investments are expected to be sufficient to fund milestone achievements and operations into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
News
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced promising clinical activity in heavily pretreated patients with recurrent glioblastoma (GBM) expressing epidermal growth factor receptor (EGFR) alterations. BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, demonstrated encouraging results in Phase 1 clinical trial, with 22 patients showing efficacy, including 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months. Additionally, 1 patient achieved a confirmed partial response and 8 patients experienced stable disease. Safety data revealed no new signals, with primarily Grade 1 and 2 diarrhea and rash. Enrollment is ongoing in a 'window of opportunity' clinical trial to assess PK and PD in brain tissue in second-line patients with high-grade glioma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
clinical trial
News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced that its President and CEO, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats at two investor conferences in November 2023. Webcasts will be available on the company's website, with replays accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
conferences
Stock BDTX logo
Black Diamond Therapeutics Inc

Nasdaq:BDTX

BDTX Rankings

#3402 Ranked by Market Cap
#3528 Ranked by Stock Gains
N/A Ranked by Dividends

BDTX Stock Data

278.24M
35.92M
2.61%
93.57%
3.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About BDTX

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.